Recent advances in Monoclonal antibodies based formulation used in the management of CRC

Abstract

One of the most frequent malignancies in the world is colorectal cancer (CRC), killing millions of people each year. Many therapeutic antibodies have been developed as key sources of blockbuster medications for colorectal cancer therapy as a result of recent developments in recombinant DNA technology. In last 20 years, mab-based cancer treatments have been the most successful therapeutic method for both solid tumors and hematologic malignancies. Moreover, we examine the present state of monoclonal antibodies in clinical development and FDA approval for colorectal cancer therapy. These antibodies are used in drug targeting delivery and recognition of cancer cells specifically. Among all the monoclonal antibodies used for colorectal cancer bevacizumab, cetuximab, and panitumumab are used prominently as compared to others like ramucirumab, onartuzumab, nivolumab, and ipilimumab. In this article, we studied a different type of formulation used in colorectal cancer based on monoclonal antibodies. Mainly used formulations are nanoparticles, nanotubes, immunoliposomes, micelles, alginate beds, hydrogels, nano micelles, nanocages, and liposomes. Among all these formulations, nanoparticles conjugated with antibodies show the targeted release, best penetration efficacy, compatibility, stability, and enhance the activity of a drug.